[424B3] CERO THERAPEUTICS HOLDINGS, INC. Prospectus Filed Pursuant to Rule 424(b)(3)
Cero Therapeutics Holdings, Inc. filed Prospectus Supplement No. 11 to its S‑1, covering 2,100,000 shares of common stock and updating its prospectus with an attached Form 8‑K. The supplement incorporates the company’s latest disclosure into the existing offering materials.
The company reports that a Nasdaq Hearings Panel denied continued listing; CERO common stock will be suspended from trading at the open on October 31, 2025. Cero has requested review by the Nasdaq Listing and Hearing Review Council and has begun the process to trade on the OTC Markets, noting that OTC is a less liquid venue that may materially affect trading price and volume. The company is also considering other exchange listing alternatives.
Cero plans to continue its clinical trials of CER‑1236. Early observations in the first three AML patients at an initial low dose showed rapid CER‑1236 cell expansion with no toxicity; a second patient receiving three successive low doses remains on trial. The company is progressing to a planned higher dose and is reviewing cash resources and financing alternatives, with no assurance of obtaining financing.
Cero Therapeutics Holdings, Inc. ha presentato il Prospetto Integrativo n. 11 al proprio S‑1, coprendo 2.100.000 azioni ordinarie e aggiornando il prospetto con un allegato Form 8‑K. Il supplemento incorpora l’ultima disclosure dell’azienda nei materiali di offerta esistenti.
La società informa che un Nasdaq Hearings Panel ha negato la continuazione della quotazione; le azioni ordinarie CERO sarà sospese dalla negoziazione all’apertura del 31 ottobre 2025. Cero ha richiesto una revisione al Nasdaq Listing and Hearing Review Council e ha avviato il processo per negoziare sui mercati OTC, evidenziando che l’OTC è un mercato meno liquido che potrebbe influire in modo sostanziale sul prezzo e sul volume delle negoziazioni. La società sta anche valutando altre alternative di quotazione su diversi listini.
Cero prevede di continuare i suoi studi clinici su CER‑1236. Osservazioni iniziali nei primi tre pazienti AML a una dose iniziale bassa hanno mostrato una rapida espansione delle cellule CER‑1236 senza tossicità; un secondo paziente che ha ricevuto tre dosi basse successive resta in corso di studio. L’azienda sta procedendo verso una dose pianificata più alta e sta riesaminando risorse finanziarie e alternative di finanziamento, senza alcuna garanzia di ottenere finanziamenti.
Cero Therapeutics Holdings, Inc. presentó el Suplemento de Prospecto No. 11 a su S‑1, que cubre 2.100.000 acciones ordinarias y actualiza su prospecto con un Formulario 8‑K adjunto. El suplemento incorpora la última divulgación de la empresa en los materiales de oferta existentes.
La empresa informa que un Panel de Audiencias de Nasdaq negó la continuación de la cotización; las acciones ordinarias de CERO serán suspendidas de la negociación al inicio del 31 de octubre de 2025. Cero ha solicitado revisión ante Nasdaq Listing and Hearing Review Council y ha iniciado el proceso para negociar en los OTC Markets, señalando que OTC es un lugar de menor liquidez que podría afectar materialmente el precio y el volumen de la negociación. La empresa también está considerando otras alternativas de cotización en bolsa.
Cero planea continuar sus ensayos clínicos de CER‑1236. Las observaciones tempranas en los primeros tres pacientes AML con una dosis inicial baja mostraron una rápida expansión de las células CER‑1236 sin toxicidad; un segundo paciente que recibió tres dosis bajas sucesivas permanece en el ensayo. La empresa está avanzando hacia una dosis más alta planificada y está revisando los recursos de efectivo y las alternativas de financiamiento, sin garantía de obtener financiamiento.
Cero Therapeutics Holdings, Inc.는 S‑1에 대한 Prospectus Supplement No. 11을 제출하여 2,100,000주의 보통주를 포함하고 첨부된 Form 8‑K로 프로스펙트를 업데이트합니다. 보충서는 기존의 공모 자료에 회사의 최신 공시를 반영합니다.
회사는 Nasdaq 청문회 패널이 상장 유지를 거부했다고 보고합니다; CERO의 보통주는 2025년 10월 31일 시초가에 거래가 중단될 예정입니다. Cero는 Nasdaq Listing and Hearing Review Council에 대한 검토를 요청했고 OTC Markets에서 거래하기 위한 절차를 시작했습니다. OTC는 유동성이 낮아 거래가에 상당한 영향을 줄 수 있다고 밝혔으며, 회사는 또한 다른 거래소 상장 대안을 고려하고 있습니다.
Cero는 CER‑1236의 임상 시험을 계속할 계획입니다. 초기 낮은 용량으로 AML의 초기 세 명의 환자에서의 조기 관찰은 독성 없이 CER‑1236 세포의 빠른 확장을 보였고; 연속으로 세 번의 낮은 용량을 받은 두 번째 환자는 여전히 연구에 남아 있습니다. 회사는 계획된 더 높은 용량으로 진행 중이며 현금 자원과 금융 대안을 검토하고 있으며 자금 조달을 확보한다는 보장은 없습니다.
Cero Therapeutics Holdings, Inc. a déposé le Prospectus Supplément No. 11 à son S‑1, couvrant 2 100 000 actions ordinaires et met à jour son prospectus avec le formulaire 8‑K joint. Le supplément intègre la dernière divulgation de la société dans les matériaux d’offre existants.
La société indique qu’un panel d’auditions de Nasdaq a refusé la poursuite de la cotation; l’action ordinaire de CERO sera suspendue à l’ouverture le 31 octobre 2025. Cero a demandé un réexamen par le Nasdaq Listing and Hearing Review Council et a entamé la procédure pour négocier sur les OTC Markets, précisant que l’OTC est un marché moins liquide qui pourrait influencer de manière significative le prix et le volume des échanges. La société envisage également d’autres alternatives de cotation en bourse.
Cero prévoit de poursuivre ses essais cliniques de CER‑1236. Les observations précoces chez les trois premiers patients atteints de AML avec une dose initiale faible ont montré une expansion rapide des cellules CER‑1236 sans toxicité; un second patient ayant reçu trois doses faibles successives reste en essai. La société progresse vers une dose plus élevée prévue et examine les ressources de trésorerie et les options de financement, sans assurance d’obtenir un financement.
Cero Therapeutics Holdings, Inc. hat Prospektzusatz Nr. 11 zu seinem S‑1 eingereicht, der 2.100.000 Stammaktien umfasst und aktualisiert seinen Prospekt mit dem beigefügten Formular 8‑K. Der Zusatz integriert die neuesten Offenlegungen des Unternehmens in das bestehende Angebotmaterial.
Das Unternehmen meldet, dass ein Nasdaq Hearings Panel die weiterhin Listung verweigert hat; CERO Stammaktien werden zum Handelsbeginn am 31. Oktober 2025 ausgesetzt. Cero hat eine Überprüfung durch das Nasdaq Listing and Hearing Review Council beantragt und den Prozess eingeleitet, an den OTC Markets gehandelt zu werden, wobei darauf hingewiesen wird, dass OTC ein weniger liquides Handelssystem ist, das den Handelspreis und das Handelsvolumen wesentlich beeinflussen kann. Das Unternehmen erwägt auch andere Börsennotierungsalternativen.
Cero plant, seine klinischen Studien von CER‑1236 fortzusetzen. Frühe Beobachtungen bei den ersten drei AML‑Patienten bei einer anfänglichen niedrigen Dosis zeigten eine rasche Expansion der CER‑1236‑Zellen ohne Toxizität; ein zweiter Patient, der drei aufeinanderfolgende niedrige Dosen erhielt, bleibt im Versuch. Das Unternehmen kommt zu einer geplanten höheren Dosis voran und prüft Bargeldressourcen und Finanzierungsmöglichkeiten, ohne Gewissheit, eine Finanzierung zu erhalten.
قدمت Cero Therapeutics Holdings, Inc. التكميل الاسترشادي رقم 11 إلى نموذج S‑1، يغطي 2,100,000 سهماً عادياً وتحديث نشرتها باستخدام النموذج 8‑K المرفق. يدمج الملحق أحدث الكشف من الشركة في مواد العرض القائمة.
تورد الشركة أن فريق جلسات الاستماع في ناسداك رفض الاستمرار في الإدراج؛ ستعلق أسهم CERO العادية عن التداول عند الافتتاح في 31 أكتوبر 2025. طلبت Cero مراجعة من مجلس مراجعة الإدراج والاستماع في ناسداك وبدأت عملية التداول في أسواق OTC، مع الإشارة إلى أن OTC هو مكان أقل سيولة قد يؤثر بشكل مادي على سعر التداول وحجم التداول. كما تدرس الشركة بدائل إدراج أخرى في البورصات.
تخطط Cero لمواصلة تجارب CER‑1236 السريرية. لوحظت ملاحظات مبكرة في أول ثلاث مرضى AML عند جرعة منخفضة أولية بانفراج سريعي لخلايا CER‑1236 دون سمية؛ المريض الثاني الذي تلقى ثلاث جرعات منخفضة متتالية ما زال في الاختبار. تتقدم الشركة نحو جرعة أعلى مخططة وتراجع الموارد النقدية وخيارات التمويل، دون ضمان بالحصول على تمويل.
- None.
- Nasdaq trading suspension effective at the open on October 31, 2025
- Potential OTC Markets transition flagged as less liquid, which may materially affect price and volume
Insights
Nasdaq suspension is a material listing setback; clinical work continues.
Cero Therapeutics filed a prospectus supplement referencing an 8‑K that discloses a Nasdaq Hearings Panel denial, leading to a trading suspension on
Operationally, Cero states it will continue clinical development of CER‑1236. Early observations in three AML patients at an initial low dose noted rapid cell expansion and no toxicity, and a second patient remains on trial after three low doses. The company plans higher‑dose escalation and is assessing financing alternatives; outcomes will hinge on access to capital and future disclosures.
Cero Therapeutics Holdings, Inc. ha presentato il Prospetto Integrativo n. 11 al proprio S‑1, coprendo 2.100.000 azioni ordinarie e aggiornando il prospetto con un allegato Form 8‑K. Il supplemento incorpora l’ultima disclosure dell’azienda nei materiali di offerta esistenti.
La società informa che un Nasdaq Hearings Panel ha negato la continuazione della quotazione; le azioni ordinarie CERO sarà sospese dalla negoziazione all’apertura del 31 ottobre 2025. Cero ha richiesto una revisione al Nasdaq Listing and Hearing Review Council e ha avviato il processo per negoziare sui mercati OTC, evidenziando che l’OTC è un mercato meno liquido che potrebbe influire in modo sostanziale sul prezzo e sul volume delle negoziazioni. La società sta anche valutando altre alternative di quotazione su diversi listini.
Cero prevede di continuare i suoi studi clinici su CER‑1236. Osservazioni iniziali nei primi tre pazienti AML a una dose iniziale bassa hanno mostrato una rapida espansione delle cellule CER‑1236 senza tossicità; un secondo paziente che ha ricevuto tre dosi basse successive resta in corso di studio. L’azienda sta procedendo verso una dose pianificata più alta e sta riesaminando risorse finanziarie e alternative di finanziamento, senza alcuna garanzia di ottenere finanziamenti.
Cero Therapeutics Holdings, Inc. presentó el Suplemento de Prospecto No. 11 a su S‑1, que cubre 2.100.000 acciones ordinarias y actualiza su prospecto con un Formulario 8‑K adjunto. El suplemento incorpora la última divulgación de la empresa en los materiales de oferta existentes.
La empresa informa que un Panel de Audiencias de Nasdaq negó la continuación de la cotización; las acciones ordinarias de CERO serán suspendidas de la negociación al inicio del 31 de octubre de 2025. Cero ha solicitado revisión ante Nasdaq Listing and Hearing Review Council y ha iniciado el proceso para negociar en los OTC Markets, señalando que OTC es un lugar de menor liquidez que podría afectar materialmente el precio y el volumen de la negociación. La empresa también está considerando otras alternativas de cotización en bolsa.
Cero planea continuar sus ensayos clínicos de CER‑1236. Las observaciones tempranas en los primeros tres pacientes AML con una dosis inicial baja mostraron una rápida expansión de las células CER‑1236 sin toxicidad; un segundo paciente que recibió tres dosis bajas sucesivas permanece en el ensayo. La empresa está avanzando hacia una dosis más alta planificada y está revisando los recursos de efectivo y las alternativas de financiamiento, sin garantía de obtener financiamiento.
Cero Therapeutics Holdings, Inc.는 S‑1에 대한 Prospectus Supplement No. 11을 제출하여 2,100,000주의 보통주를 포함하고 첨부된 Form 8‑K로 프로스펙트를 업데이트합니다. 보충서는 기존의 공모 자료에 회사의 최신 공시를 반영합니다.
회사는 Nasdaq 청문회 패널이 상장 유지를 거부했다고 보고합니다; CERO의 보통주는 2025년 10월 31일 시초가에 거래가 중단될 예정입니다. Cero는 Nasdaq Listing and Hearing Review Council에 대한 검토를 요청했고 OTC Markets에서 거래하기 위한 절차를 시작했습니다. OTC는 유동성이 낮아 거래가에 상당한 영향을 줄 수 있다고 밝혔으며, 회사는 또한 다른 거래소 상장 대안을 고려하고 있습니다.
Cero는 CER‑1236의 임상 시험을 계속할 계획입니다. 초기 낮은 용량으로 AML의 초기 세 명의 환자에서의 조기 관찰은 독성 없이 CER‑1236 세포의 빠른 확장을 보였고; 연속으로 세 번의 낮은 용량을 받은 두 번째 환자는 여전히 연구에 남아 있습니다. 회사는 계획된 더 높은 용량으로 진행 중이며 현금 자원과 금융 대안을 검토하고 있으며 자금 조달을 확보한다는 보장은 없습니다.
Cero Therapeutics Holdings, Inc. a déposé le Prospectus Supplément No. 11 à son S‑1, couvrant 2 100 000 actions ordinaires et met à jour son prospectus avec le formulaire 8‑K joint. Le supplément intègre la dernière divulgation de la société dans les matériaux d’offre existants.
La société indique qu’un panel d’auditions de Nasdaq a refusé la poursuite de la cotation; l’action ordinaire de CERO sera suspendue à l’ouverture le 31 octobre 2025. Cero a demandé un réexamen par le Nasdaq Listing and Hearing Review Council et a entamé la procédure pour négocier sur les OTC Markets, précisant que l’OTC est un marché moins liquide qui pourrait influencer de manière significative le prix et le volume des échanges. La société envisage également d’autres alternatives de cotation en bourse.
Cero prévoit de poursuivre ses essais cliniques de CER‑1236. Les observations précoces chez les trois premiers patients atteints de AML avec une dose initiale faible ont montré une expansion rapide des cellules CER‑1236 sans toxicité; un second patient ayant reçu trois doses faibles successives reste en essai. La société progresse vers une dose plus élevée prévue et examine les ressources de trésorerie et les options de financement, sans assurance d’obtenir un financement.
Cero Therapeutics Holdings, Inc. hat Prospektzusatz Nr. 11 zu seinem S‑1 eingereicht, der 2.100.000 Stammaktien umfasst und aktualisiert seinen Prospekt mit dem beigefügten Formular 8‑K. Der Zusatz integriert die neuesten Offenlegungen des Unternehmens in das bestehende Angebotmaterial.
Das Unternehmen meldet, dass ein Nasdaq Hearings Panel die weiterhin Listung verweigert hat; CERO Stammaktien werden zum Handelsbeginn am 31. Oktober 2025 ausgesetzt. Cero hat eine Überprüfung durch das Nasdaq Listing and Hearing Review Council beantragt und den Prozess eingeleitet, an den OTC Markets gehandelt zu werden, wobei darauf hingewiesen wird, dass OTC ein weniger liquides Handelssystem ist, das den Handelspreis und das Handelsvolumen wesentlich beeinflussen kann. Das Unternehmen erwägt auch andere Börsennotierungsalternativen.
Cero plant, seine klinischen Studien von CER‑1236 fortzusetzen. Frühe Beobachtungen bei den ersten drei AML‑Patienten bei einer anfänglichen niedrigen Dosis zeigten eine rasche Expansion der CER‑1236‑Zellen ohne Toxizität; ein zweiter Patient, der drei aufeinanderfolgende niedrige Dosen erhielt, bleibt im Versuch. Das Unternehmen kommt zu einer geplanten höheren Dosis voran und prüft Bargeldressourcen und Finanzierungsmöglichkeiten, ohne Gewissheit, eine Finanzierung zu erhalten.
قدمت Cero Therapeutics Holdings, Inc. التكميل الاسترشادي رقم 11 إلى نموذج S‑1، يغطي 2,100,000 سهماً عادياً وتحديث نشرتها باستخدام النموذج 8‑K المرفق. يدمج الملحق أحدث الكشف من الشركة في مواد العرض القائمة.
تورد الشركة أن فريق جلسات الاستماع في ناسداك رفض الاستمرار في الإدراج؛ ستعلق أسهم CERO العادية عن التداول عند الافتتاح في 31 أكتوبر 2025. طلبت Cero مراجعة من مجلس مراجعة الإدراج والاستماع في ناسداك وبدأت عملية التداول في أسواق OTC، مع الإشارة إلى أن OTC هو مكان أقل سيولة قد يؤثر بشكل مادي على سعر التداول وحجم التداول. كما تدرس الشركة بدائل إدراج أخرى في البورصات.
تخطط Cero لمواصلة تجارب CER‑1236 السريرية. لوحظت ملاحظات مبكرة في أول ثلاث مرضى AML عند جرعة منخفضة أولية بانفراج سريعي لخلايا CER‑1236 دون سمية؛ المريض الثاني الذي تلقى ثلاث جرعات منخفضة متتالية ما زال في الاختبار. تتقدم الشركة نحو جرعة أعلى مخططة وتراجع الموارد النقدية وخيارات التمويل، دون ضمان بالحصول على تمويل.
Filed Pursuant to Rule 424(b)(3)
Registration No. 333-283492
Prospectus Supplement No. 11
(To Prospectus dated May 23, 2025, as supplemented by
Prospectus Supplement No. 1 dated June 6, 2025
Prospectus Supplement No. 2 dated June 16, 2025
Prospectus Supplement No. 3 dated June 25, 2025
Prospectus Supplement No. 4 dated July 2, 2025
Prospectus Supplement No. 5 dated July 14, 2025
Prospectus Supplement No. 6 dated July 25, 2025
Prospectus Supplement No. 7 dated August 22, 2025
Prospectus Supplement No. 8 dated September 4, 2025
Prospectus Supplement No. 9 dated September 5, 2025
Prospectus Supplement No. 10 dated October 23, 2025)
CERO THERAPEUTICS HOLDINGS, INC.
2,100,000 Shares of Common Stock
This prospectus supplement no. 11 (this “Prospectus Supplement”) amends and supplements the prospectus dated May 23, 2025 (as may be supplemented or amended from time to time, the “Prospectus”), which forms part of our Registration Statement on Form S-1 (Registration Statement No. 333-283492), as amended by Post-Effective Amendment No. 1 thereto. This Prospectus Supplement is being filed to update and supplement the information included or incorporated by reference in the Prospectus with the information contained in the attached Current Report on Form 8-K, filed with the Securities and Exchange Commission (the “Securities and Exchange Commission”) on October 30, 2025 (the “Form 8-K”). Accordingly, we have attached the Form 8-K to this Prospectus Supplement.
This Prospectus Supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This Prospectus Supplement should be read in conjunction with the Prospectus, and if there is any inconsistency between the information in the Prospectus and this Prospectus Supplement, you should rely on this Prospectus Supplement.
Our common stock and public warrants are listed on Nasdaq Capital Market (“Nasdaq”) under the symbols “CERO” and “CEROW,” respectively. On October 29, 2025, the last quoted sale price of our common stock as reported on Nasdaq was $1.79 per share and the last quoted sale price of our public warrants as reported on Nasdaq was $0.0127 per warrant.
We are an “emerging growth company” under applicable federal securities laws and will be subject to reduced public company reporting requirements.
Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our securities in “Risk Factors” beginning on page 8 of the Prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities to be issued under the Prospectus or determined if the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this Prospectus Supplement is October 30, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or Section 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 29, 2025
CERO THERAPEUTICS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-40877 | 87-1088814 | ||
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) | (I.R.S. Employer Identification Number) |
| 201 Haskins Way, Suite 230, South San Francisco, CA |
94080 | |
| (Address of principal executive offices) | (Zip Code) |
(650) 407-2376
Registrant’s telephone number, including area code
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Common stock, par value $0.0001 per share | CERO | NASDAQ Capital Market | ||
| Warrants, each whole warrant exercisable for one two-thousandths of a share of common stock | CEROW | NASDAQ Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
As previously disclosed, on August 28, 2025, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), received a letter from the staff at the Nasdaq Listing Qualifications department notifying the Company that such staff had determined that the Company does not comply with the minimum stockholders’ equity requirement of $2,500,000 (the “Stockholders’ Equity Requirement”) for continued listing on the Nasdaq Capital Market (“Nasdaq”) set forth in Nasdaq Rule 5550(b).
As also previously disclosed, on September 3, 2025, the Company requested a hearing to appeal such determination before a panel (the “Hearings Panel”). On October 29, 2025, the Company received the determination of the Hearings Panel to deny the Company’s request for the continued listing of its common stock. As a result, the common stock will be suspended from trading on Nasdaq at open of trading on October 31, 2025.
The Company has submitted a request for review of the Hearings Panel’s decision by the Nasdaq Listing and Hearing Review Council (the “Council”). The Company has also commenced the process of seeking to trade its shares of common stock on the OTC Markets. However, the Company can provide no assurance that the review by the Council will result in the continued listing of its shares of common stock or that the shares of common stock will be admitted for trading on the OTC Markets. The OTC Markets also are a less liquid market than Nasdaq, which may have a material adverse effect on the trading price and volume for the common stock. The Company is also considering listing alternatives, including applying to list its shares of common stock on another securities exchange.
The Company currently plans to continue its clinical trials, including the dosing of patients in such trials. As described previously by CERO, evidence gathered for CER-1236 in the first three AML cancer patients dosed at the initial low dose showed rapid cell expansion of CER-1236 in these patients, along with observation of no toxicity. Moreover the second patient, infused with three of the low doses in succession, continues on trial. The company believes these early stage observations support continued clinical development of CER-1236 at the planned higher dose, and is progressing on this plan. The Company is currently reviewing its cash resources and potential financing alternatives to fund its continued operations. The Company can provide no assurance that it will be able to obtain such financing on acceptable terms, or at all.
Item 8.01. Other Events.
On October 29, 2025, the Company issued a press release announcing the Hearings Panel’s determination. Such press release is filed as Exhibit 99.1 hereto and is hereby incorporated by reference herein.
Item 9.01 Exhibits.
(d) Exhibits.
| Exhibit Number |
Description | |
| 99.1 | Press Release dated October 29, 2025 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CERO THERAPEUTICS HOLDINGS, INC. | ||
| By: | /s/ Chris Ehrlich | |
| Name: | Chris Ehrlich | |
| Title: | Chief Executive Officer | |
Dated: October 29, 2025
2
FAQ
What did CERO (CERO) file and what does it cover?
What is the status of CERO’s Nasdaq listing?
Is CERO pursuing alternatives after the Nasdaq decision?
How might an OTC Markets listing affect CERO shares?
What clinical trial updates did CERO provide?
Is CERO securing financing for ongoing operations?
